2269 N Stock Overview
An investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
WuXi Biologics (Cayman) Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$62.53 |
| 52 Week High | HK$62.53 |
| 52 Week Low | HK$62.53 |
| Beta | 0.66 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -74.45% |
| 5 Year Change | n/a |
| Change since IPO | -73.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2269 N | MX Life Sciences | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how 2269 N performed against the MX Life Sciences industry.
Return vs Market: Insufficient data to determine how 2269 N performed against the MX Market.
Price Volatility
| 2269 N volatility | |
|---|---|
| 2269 N Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: 2269 N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 2269 N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 12,397 | Chris Chen | www.wuxibiologics.com |
WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development, and manufacturing in the People’s Republic of China, North America, Europe, and internationally. It also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine contract development and manufacturing organization (CDMO) and related business; and material supplier activities. The company has a research service agreement with BioNTech SE to discover and investigate monoclonal antibodies for developing next-generation therapeutic product candidates.
WuXi Biologics (Cayman) Inc. Fundamentals Summary
| 2269 N fundamental statistics | |
|---|---|
| Market cap | Mex$132.67b |
| Earnings (TTM) | Mex$9.71b |
| Revenue (TTM) | Mex$38.71b |
Is 2269 N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2269 N income statement (TTM) | |
|---|---|
| Revenue | CN¥16.55b |
| Cost of Revenue | CN¥9.68b |
| Gross Profit | CN¥6.87b |
| Other Expenses | CN¥2.72b |
| Earnings | CN¥4.15b |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Mar 26, 2024
| Earnings per share (EPS) | 0.99 |
| Gross Margin | 41.51% |
| Net Profit Margin | 25.08% |
| Debt/Equity Ratio | 7.7% |
How did 2269 N perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/03/18 01:23 |
| End of Day Share Price | 2023/12/20 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
WuXi Biologics (Cayman) Inc. is covered by 48 analysts. 32 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bo Li | BofA Global Research |
| Shun Kei Law | CCB International Securities Limited |
| Jian Xiong Lim | CFRA Equity Research |